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A 64-year-old woman who complained of abdominal pain underwent right radical nephrectomy under
the clinical diagnosis of renal cell carcinoma in January, 2006. The pathological diagnosis was
leiomyosarcoma originating from the kidney. Follow-up computed tomography revealed 2 small nodules in
the left lung 15 months after nephrectomy. A lung nodule resected with video-assisted thoracic surgery
(VATS) was identified as metastatic leiomyosarcoma. Since the pulmonary metastases progressed after
VATS, systemic chemotherapy with gemcitabine and docetaxel (GD therapy) was started. The lung
metastases responded well, and a durable partial response was achieved for 29 months. Subsequently, the
patient developed new pulmonary metastases and pancreatic metastasis. Despite this disease progression,
we elected to continue GD therapy, since the patient's performance status and quality of life were favorable
during the treatment. So far, the GD therapy has been continued for another 23 months, for a total of 41
treatment cycles, with few adverse events. Although multiple metastases have slowly progressed, the patient
has maintained good performance status in the outpatient clinic. In the present case, GD therapy seems to
have been beneficial for survival, as metastatic renal leiomyosarcoma is considered to have an extremely poor
prognosis.
(Hinyokika Kiyo 59 : 497-501, 2013)




発肺転移を来たした症例に gemcitabine および doce-
taxel 併用療法 (GD 療法）を行い，長期生存が得られ
た症例を経験したので報告する．
症 例
患 者 : 64歳，女性






施行した．病理組織学的所見から Fig. 1B，C，D に示
すように腎被膜から発生した平滑筋肉腫と診断した．







入院時身体所見 : 身長 154.3 cm，体重 53.4 kg．上











Fig. 1. A : CT scan showed a 120 mm well-enhanced and circumscribed mass with necrosis in the lower pole of
the right kidney. B : Macroscopic findings of right renal tumor. C : Microscopic findings of right renal
tumor stained with Hematoxylin-Eosin (×400). D : Immunostaining findings for α-SMA, right renal
tumor (×400). E : Microscopic findings of left lung nodule stained with Hematoxylin-Eosin (×400).
腹部正中に手術痕を認めた．




入院時画像検査 : 2008年 4月の CT では，2007年10
月に比し，右肺尖部，右肺中葉，左肺尖部を始めとし
た多発肺転移は，いずれも増大傾向を認めた．結果と
して肺転移の長径和は 11 mm から 18 mm に増大して
いた (Fig. 2）．
治療経過 : 2008年 3月より全身化学療法として GD
療法を開始した．GD 療法は 800 mg/m2 の gemci-
tabine を第 1および 8日，60 mg/m2 の docetaxel を第
8 日に投与し， 3 週サイクルで開始した．また，各
コースにおいて第10∼12日に G-CSF 製剤を予防的に
投与した． 6コース施行後の効果判定では肺転移巣は
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Fig. 2. Progression of pulmonary metastasis before and shortly after
chemotherapy. * Sum of longest diameter of 3 lesions
changed from 11 mm to 18 mm.
長径和で 22 mmから 14 mm へと縮小し，RECIST 上
partial response (PR) と判定された．有害事象は軽度




3コースごとの CT 評価で stable disease を維持してい
たため12コースからは 6週サイクル，18コースからは
泌59,08,04-3
Fig. 3. Change in tumor burden during the treatment. *1 Pulmonary metastasis
(sum of longest diameter of 3 main lesions). *2 The common adverse
events were grade 1 myelosuppression (G-CSF was given for 3 days) and
grade 2 peripheral neuropathy. *3 PR ; partial response.
8週サイクルとした．その後 GD 療法を Fig. 3 に示す
経過で計25コース施行した．その後2010年には肺転移
の増大および膵転移の新出を認めたため，この時点で
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Fig. 4. Progression of metastasis after progressive disease (PD).
* The progression of each metastatic lesion was slow even






な performance status (PS) が保たれている．2012年11































に gemcitabine 900 mg/m2，第 8日に docetaxel 100 mg/
m2 を点滴静注し，21日サイクルで行うというもの
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療を行っている．有害事象は軽微であり，患者の

































1) Campbell SC, Novick AC and Bukowski RM : Renal
tumors, Campbell-Walsh Urology, Edited by Kavoussi
LR, Novick AC, Partin AW, et al. 9th Edition, pp
1632-1634, Saunders/Elsevier, Philadelphia, 2007
2) Wang X, Xu R, Yan L, et al. : Adult renal sarcoma :
clinical features and survival in a series of patients
treated at a high-volume institution. Urology 77 :
836-841, 2011
3) Deyrup AT, Montgomery E and Fisher C : Leiomyo-
sarcoma of the kidney : a clinicopathologic study. Am
J SurgPathol 28 : 178-182, 2004
4) Maki RG : Gemcitabine and docetaxel in metastatic
sarcoma : past, present, and future. Oncologist 12 :
999-1006, 2007
5) Movva S and Verschraegen C : Systemic management
strategies for metastatic soft tissue sarcoma. Drugs
71 : 2115-2129, 2011
6) Hensley ML, Maki R, Venkatraman E, et al. : Gemci-
tabine and docetaxel in patients with unresectable
leiomyosarcoma : results of a phase II trial. J Clin
Oncol 20 : 2824-2831, 2002
7) Hensley ML, Blessing JA, Degeest K, et al. : Fixed-
dose rate gemcitabine plus docetaxel as second-line
therapy for metastatic uterine leiomyosarcoma : a
gynecologic oncology group phase II study. Gynecol
Oncol 109 : 323-328, 2008
8) Bay JO, Ray-Coquard I, Fayette J, et al. : Groupe
SarcomeFrançais : docetaxel and gemcitabine combi-
nation in 133 advanced soft-tissue sarcomas : a retro-
spective analysis. Int J Cancer 119 : 706-711, 2006
9) Penel N, Van Glabbeke M, Marreaud S, et al. : Testing
new regimens in patients with advanced soft tissue
sarcoma : analysis of publications from the last 10
years. Ann Oncol 22 : 1266-1272, 2011
10) van der Graaf WT, Blay JY, Chawla SP, et al. : Pazo-
panib for metastatic soft-tissue sarcoma (PALETTE) :
a randomized, double-blind, placebo-controlled phase
3 trial. Lancet 379 : 1879-1886, 2012
(
Received on January 25, 2013
)Accepted on March 28, 2013
南雲，ほか : 平滑筋肉腫・化学療法 501
